Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur 610005, India.
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong 999077, China.
World J Gastroenterol. 2024 Sep 21;30(35):3965-3971. doi: 10.3748/wjg.v30.i35.3965.
In this editorial, we examine a paper by Koizumi , on the role of peroxisome proliferator-activated receptor (PPAR) agonists in alcoholic liver disease (ALD). The study determined whether elafibranor protected the intestinal barrier and reduced liver fibrosis in a mouse model of ALD. The study also underlines the role of PPARs in intestinal barrier function and lipid homeostasis, which are both affected by ALD. Effective therapies are necessary for ALD because it is a critical health issue that affects people worldwide. This editorial analyzes the possibility of PPAR agonists as treatments for ALD. As key factors of inflammation and metabolism, PPARs offer multiple methods for managing the complex etiology of ALD. We assess the abilities of PPARα, PPARγ, and PPARβ/δ agonists to prevent steatosis, inflammation, and fibrosis due to liver diseases. Recent research carried out in preclinical and clinical settings has shown that PPAR agonists can reduce the severity of liver disease. This editorial discusses the data analyzed and the obstacles, advantages, and mechanisms of action of PPAR agonists for ALD. Further research is needed to understand the efficacy, safety, and mechanisms of PPAR agonists for treating ALD.
在这篇社论中，我们研究了 Koizumi 等人关于过氧化物酶体增殖物激活受体 (PPAR) 激动剂在酒精性肝病 (ALD) 中的作用的论文。该研究旨在确定依帕司他是否能保护肠道屏障并减轻 ALD 小鼠模型中的肝纤维化。该研究还强调了 PPAR 在肠道屏障功能和脂质平衡中的作用，这两者均受 ALD 影响。由于 ALD 是一个影响全球人民健康的重大问题，因此需要有效的治疗方法。本社论分析了 PPAR 激动剂作为 ALD 治疗方法的可能性。作为炎症和代谢的关键因素，PPAR 为管理 ALD 的复杂病因提供了多种方法。我们评估了 PPARα、PPARγ 和 PPARβ/δ 激动剂预防因肝脏疾病导致的脂肪变性、炎症和纤维化的能力。在临床前和临床环境中进行的最新研究表明，PPAR 激动剂可以减轻肝病的严重程度。本社论讨论了分析的数据以及 PPAR 激动剂治疗 ALD 的障碍、优势和作用机制。需要进一步研究以了解 PPAR 激动剂治疗 ALD 的疗效、安全性和作用机制。
